In part 1 , patients were sequentially enrolled to receive paclitaxel 200 mg/m ( 2 ) and carboplatin ( area under the concentration-versus-time curve , 6 mg/min/ml ) plus panitumumab ( 1.0 , 2.0 , or 2.5 mg/kg ) .